Author

R. Sherburn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Organism:human· 1 Organism:mouse· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

M. Pazgier· 3 shared S. Ding· 3 shared W. D. Tolbert· 3 shared A. Finzi· 2 shared D. N. Nguyen· 2 shared D. Wu· 2 shared G. Beaudoin-Bussieres· 2 shared G. Piszczek· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

M. Pazgier

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Piperidine CD4-mimetic compounds expose vulnerable Env epitopes sensitizing HIV-1-infected cells to ADCC

S. Ding, W. D. Tolbert, H. Zhu, D. Lee, T. Higgins, X. Zhao, D. Nguyen, R. Sherburn, J. Richard, G. Gendron-Lepage, H. Medjahed, M. Mohammadi, C. Abrams, M. Pazgier, A. B. Smith, A. Finzi

The paper describes piperidine-based CD4-mimetic compounds that expose HIV-1 Env epitopes, increasing sensitivity to ADCC by targeting Asp368.

bioRxiv · Mar 23, 2023 · PreprintImmunology

Molecular basis for antiviral activity of pediatric neutralizing antibodies targeting SARS-CoV-2 Spike receptor binding domain

Y. Chen, J. Prevost, I. Ullah, H. Romero, V. Lisi, W. D. Tolbert, J. R. Grover, S. Ding, S. Y. Gong, G. Beaudoin-Bussieres, R. Gasser, M. Benlarbi, D. Vezina, S. P. Anand, D. Chatterjee, , A. Finzi

This study identifies two potent neutralizing antibodies, EH3 and EH8, from a pediatric patient that cross-neutralize SARS-CoV-2 variants and provide in vivo protection against the Delta VOC.

bioRxiv · Jul 27, 2022 · PreprintMicrobiology

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities

Y. Chen, L. Sun, I. Ullah, G. Beaudoin-Bussieres, S. P. Anand, A. P. Hederman, W. D. Tolbert, R. Sherburn, D. N. Nguyen, L. Marchitto, S. Ding, D. Wu, Y. Luo, S. Gottumukkala, S. Moran, , M. Pazgier

The paper develops ACE2-Fc molecules that neutralize SARS-CoV-2 and show Fc-effector activity, effectively treating lethal infection in mice.

bioRxiv · Nov 24, 2021Microbiology